{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:48Z","timestamp":1787009448084,"version":"build-2736575974"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kaposi sarcoma (KS) is a marker of advanced HIV disease; it is still the most frequent AIDS-associated malignancy in Mexico despite universal access to antiretroviral therapy, reflecting a gap in early HIV diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The objectives of the study were to describe people with HIV with KS who died within 30 days of admission at INCan (National Cancer Institute) and to quantify resources and years of life lost (YLL). We collected demographic data, HIV-related variables, all diagnostic and therapeutic procedures, hospitalizations, and estimated YLL and disability-adjusted life years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen (6.7%) people with HIV with KS from 270 patients admitted at INCan from 2014 to 2021 were included. The median age was 31 years (IQR 27\u201336), and the median days from admission to death and from HIV diagnosis to death were 15 (IQR, 6\u201324) and 73 (IQR, 30\u2013857), respectively. Upon admission, the median HIV viral load was 314 476\u2005copies\/mL (IQR, 140 709\u2013695 613); CD4+ T cells, 93 cells\/mL (IQR 35\u2013124); and CD4\/CD8 ratio, 0.08 (IQR, 0.06\u20130.12). Coinfections were diagnosed in 14 (77.7%) patients. The average expenditure per patient was US $7685.99 USD, and the total YLL was 737.4 with a median 42 years (IQR, 37.7\u201347) per patient. The total care cost was US $183 947.48, equivalent to a screening program in key populations, which would have allowed the early detection of 1227 cases and saved 8410 disability-adjusted life years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Reinforcement of early HIV infection detection in key population programs should be prioritized to reduce KS-associated deaths and YLL and for rational use of health budgets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofae648","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T16:16:39Z","timestamp":1730132199000},"source":"Crossref","is-referenced-by-count":1,"title":["Early Mortality and Health Care Costs in Patients Recently Diagnosed With Kaposi Sarcoma at the National Cancer Institute, Mexico City"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7252-7666","authenticated-orcid":false,"given":"Daniel","family":"Carpio-Guadarrama","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Instituto Nacional de Cancerolog\u00eda , Mexico City ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0957-9509","authenticated-orcid":false,"given":"Antonio","family":"Camiro-Z\u00fa\u00f1iga","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Instituto Nacional de Cancerolog\u00eda , Mexico City ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"P\u00e9rez-Dorame","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Instituto Nacional de Cancerolog\u00eda , Mexico City ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-404X","authenticated-orcid":false,"given":"Alexandra","family":"Martin-Onra\u00ebt","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Instituto Nacional de Cancerolog\u00eda , Mexico City ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4582-1740","authenticated-orcid":false,"given":"Diana","family":"Garc\u00eda-Escutia","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Instituto Nacional de Cancerolog\u00eda , Mexico City ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8811-7103","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Mendoza-Palacios","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Instituto Nacional de Cancerolog\u00eda , Mexico City ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1991-0923","authenticated-orcid":false,"given":"Patricia","family":"Volkow-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Instituto Nacional de Cancerolog\u00eda , Mexico City ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"key":"2024112610473261100_ofae648-B1","first-page":"1","article-title":", et al. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","author":"Castro","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"2024112610473261100_ofae648-B2","first-page":"390","article-title":"The epidemiology of acquired immunodeficiency syndrome malignancies","volume":"27","author":"Goedert","year":"2000","journal-title":"Semin Oncol"},{"key":"2024112610473261100_ofae648-B3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1749-6632.1984.tb37163.x","article-title":"Malignancies in the AIDS patient: natural history, treatment strategies, and preliminary results","volume":"437","author":"Longo","year":"1984","journal-title":"Ann N Y Acad Sci"},{"key":"2024112610473261100_ofae648-B4","doi-asserted-by":"crossref","first-page":"e1566","DOI":"10.1016\/S2214-109X(23)00349-2","article-title":"Global patterns and trends in Kaposi sarcoma incidence: a population-based study","volume":"11","author":"Fu","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2024112610473261100_ofae648-B5","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2017","journal-title":"Lancet HIV"},{"key":"2024112610473261100_ofae648-B6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jnci\/dji072","article-title":"Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy","volume":"97","author":"Clifford","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2024112610473261100_ofae648-B7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1590\/S0036-36342012000500007","article-title":"High prevalence of late diagnosis of HIV in Mexico during the HAART era","volume":"54","author":"Crabtree-Ram\u00edrez","year":"2012","journal-title":"Salud Publica Mex"},{"key":"2024112610473261100_ofae648-B8","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/QAI.0000000000000645","article-title":"Implementation and operational research: effect of universal access to antiretroviral therapy on HIV\/AIDS mortality in Mexico 1990-2011","volume":"69","author":"Hern\u00e1ndez-\u00c1vila","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024112610473261100_ofae648-B9","first-page":"66","article-title":"Costos en la transfusi\u00f3n sangu\u00ednea","volume":"23","author":"Alvarez","year":"2000","journal-title":"Rev Mex Anestesiol"},{"key":"2024112610473261100_ofae648-B10","author":"World Bank Group"},{"key":"2024112610473261100_ofae648-B11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2989\/16085906.2019.1679850","article-title":"Meta-analysis of average costs of HIV testing and counselling and voluntary medical male circumcision across thirteen countries","volume":"18","author":"Pineda-Antunez","year":"2019","journal-title":"Afr J AIDS Res"},{"key":"2024112610473261100_ofae648-B12","author":"World Health Organization"},{"key":"2024112610473261100_ofae648-B13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1758-2652-13-23","article-title":"AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa","volume":"13","author":"Chu","year":"2010","journal-title":"J Int AIDS Soc"},{"key":"2024112610473261100_ofae648-B14","doi-asserted-by":"crossref","first-page":"e64392","DOI":"10.1371\/journal.pone.0064392","article-title":"Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study","volume":"8","author":"Maskew","year":"2013","journal-title":"PLoS One"},{"key":"2024112610473261100_ofae648-B15","doi-asserted-by":"crossref","first-page":"e25658","DOI":"10.1002\/jia2.25658","article-title":"Antiretroviral therapy and Kaposi's sarcoma trends and outcomes among adults with HIV in Latin America","volume":"24","author":"Castilho","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2024112610473261100_ofae648-B16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/QAD.0b013e3282f4f223","article-title":"Life-threatening exacerbation of Kaposi's sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome","volume":"22","author":"Volkow","year":"2008","journal-title":"AIDS"},{"key":"2024112610473261100_ofae648-B17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.15585\/mmwr.mm7105a2","article-title":"Association between social vulnerability and rates of HIV diagnoses among Black adults, by selected characteristics and region of residence\u2014United States, 2018","volume":"71","author":"Dailey","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024112610473261100_ofae648-B18","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/aje\/kwz252","article-title":"The population impact of late presentation with advanced HIV disease and delayed antiretroviral therapy in adults receiving HIV care in Latin America","volume":"189","author":"Belaunzar\u00e1n-Zamudio","year":"2020","journal-title":"Am J Epidemiol"},{"key":"2024112610473261100_ofae648-B19","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0956462415627735","article-title":"Steroid-exacerbated HIV-associated cutaneous Kaposi's sarcoma immune reconstitution inflammatory syndrome: \u201cwhere a good intention turns bad","volume":"27","author":"Chabria","year":"2016","journal-title":"Int J STD AIDS"},{"key":"2024112610473261100_ofae648-B20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/QAD.0000000000000993","article-title":"Steroids are a risk factor for Kaposi's sarcoma-immune reconstitution inflammatory syndrome and mortality in HIV infection","volume":"30","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2016","journal-title":"AIDS"},{"key":"2024112610473261100_ofae648-B21","doi-asserted-by":"crossref","first-page":"e0280209","DOI":"10.1371\/journal.pone.0280209","article-title":"Impact of valganciclovir therapy on severe IRIS\u2013Kaposi sarcoma mortality: an open-label, parallel, randomized controlled trial","volume":"18","author":"Volkow","year":"2023","journal-title":"PLoS One"},{"key":"2024112610473261100_ofae648-B22","doi-asserted-by":"crossref","first-page":"286.e1","DOI":"10.1016\/j.ajog.2020.08.039","article-title":"Cost of care for the initial management of cervical cancer in women with commercial insurance","volume":"224","author":"Blanco","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"2024112610473261100_ofae648-B23","doi-asserted-by":"crossref","first-page":"e0228660","DOI":"10.1371\/journal.pone.0228660","article-title":"Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France","volume":"15","author":"de Rycke","year":"2020","journal-title":"PLoS One"},{"key":"2024112610473261100_ofae648-B24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1590\/S0036-36342008000200004","article-title":"Relaci\u00f3n costo-efectividad de las intervenciones preventivas contra el c\u00e1ncer cervical en mujeres mexicanas","volume":"50","author":"Guti\u00e9rrez-Delgado","year":"2008","journal-title":"Salud Publica Mex"},{"key":"2024112610473261100_ofae648-B25","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/cid\/cix480","article-title":"Comparison of Kaposi sarcoma risk in human immunodeficiency virus\u2013positive adults across 5 continents: a multiregional multicohort study","volume":"65","author":"AIDS-Defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae648\/60557955\/ofae648.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/11\/ofae648\/60793527\/ofae648.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/11\/ofae648\/60793527\/ofae648.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T05:48:29Z","timestamp":1732600109000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae648\/7887880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae648","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,10,30]]},"article-number":"ofae648"}}